The vagina, vulva, urethra, and bladder floor share one lining rich in estrogen receptors. When estrogen goes, all four thin at once 1. The vaginal wall stops feeding its acid-producing bacteria, so the pH drifts from about 4 to 6, and that alkaline shift lets gut bacteria colonize and reach the urethra. That is why recurrent UTIs sit in the same syndrome as dryness, and why no amount of wiping fixes them 2.
Vaginal estrogen reverses all of it. A small dose on the lining rebuilds the layers, restocks the bacteria, and drops the pH; the tissue normalizes in two to four weeks 3. The dose is ten micrograms, twice a week, and your blood estrogen barely moves from baseline 4.
It works, and the UTI result is the striking one. Pooled across thirty trials and roughly six thousand women, low-dose vaginal estrogen beat both placebo and non-hormonal moisturizers on every vaginal symptom 3. For women in the repeat-UTI pattern, infections fell from 5.9 a year to 0.5 — a ninety percent drop 5, since replicated 6, and now first-line against recurrent UTI after menopause 2. One caveat: over twelve weeks, self-reported symptoms improve almost as much on placebo 7, so judge it at three months.
Pick the preparation on logistics; they relieve symptoms equally.
No progestin is needed alongside it, even with a uterus intact; the dose is too small to build up the lining 2.
The arc is unusually predictable.
- Weeks two to four: burning and dryness ease; natural lubrication starts to return 3.
- Month three: pain with sex is meaningfully better; the urgency, wake-ups, and sting when you urinate all step down.
- Year one: in the recurrent-UTI pattern, infections drop by roughly ninety percent, and you stop scheduling life around antibiotic courses 5.
If you would rather not use estrogen, vaginal DHEA inserts 11 and the oral pill ospemifene 12 both treat painful sex. Moisturizers help mild dryness only. Skip the marketed vaginal laser; the evidence is not there 2.
The fine print — when to skip it, and what people get wrong
The boxed warning naming breast cancer, stroke, and clots was copied from high-dose oral estrogen; fifty thousand vaginal users showed no such increase 8. Real cautions needing specialist input first: active estrogen-sensitive cancer, unexplained bleeding, or aromatase-inhibitor use 9.
Not "just dryness" — it is pain, urgency, infections, and vulvar burning too 10. Same molecule as the hormone pill, a thousandth of the exposure 4. A breast-cancer history is an oncologist conversation, not a flat no 9.
Two ways it "fails": stopping when symptoms clear, then blaming the lapse on the drug 2; and never raising it — fewer than half of symptomatic women ever mention it to a clinician 13.
- 1Portman DJ, Gass ML (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. link
- 2NAMS (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. link
- 3Lethaby A, Ayeleke RO, Roberts H (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. link
- 4Santen RJ (2015). Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. link
- 5Raz R, Stamm WE (1993). A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine. link
- 6Eriksen B (1999). A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology. link
- 7Mitchell CM, Reed SD, Diem S et al. (2018). Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Internal Medicine. link
- 8Crandall CJ, Hovey KM, Andrews CA et al. (2018). Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause. link
- 9ACOG (2016). The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer (Committee Opinion No. 659). link
- 10Kingsberg SA, Wysocki S, Magnus L, Krychman ML (2013). Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. Journal of Sexual Medicine. link
- 11Labrie F, Archer DF, Koltun W et al. (2016). Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. link
- 12Bachmann GA, Komi JO (2010). Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. link
- 13Nappi RE, Kokot-Kierepa M (2012). Vaginal Health: Insights, Views and Attitudes (VIVA) — results from an international survey. Climacteric. link
დაკავშირებული სახელმძღვანელოში (6)
- — Painful sex and urinary urgency often have a pelvic-floor component too; PT pairs well with local estrogen for fuller relief.
- — Vaginal dryness and recurrent UTIs often need local estrogen even if you skip systemic HRT — a separate, lower-dose tool.
- — After menopause, leaking and painful sex can come from thinning tissue, not the muscle — worth telling apart, since fixes differ.
- — Vaginal dryness and recurrent UTIs are part of the same transition — they just show up later than hot flashes.
- — After menopause, repeat UTIs are often driven by falling estrogen starving out protective vaginal bacteria — vaginal estrogen is the single biggest lever.
- — Post-menopause, dryness and entrance pain can look identical; estrogen status is what tells them apart.